Emre Şener
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Emre Şener has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Bektas Murat
Department of Cardiology, Eskisehir City Hospital
2 shared publications Bülent Görenek
Faculty of Medicine, Departmen of Cardiology Eskişehir Osmangazi University Eskişehir Turkey
2 shared publicationsAbbas Heval
Department of Cardiovascular Surgery, Eskisehir City Hospital, Turkey
1 shared publicationBarıs Ozden
Department of Cardiology, Eskisehir City Hospital, Turkey
1 shared publicationErdi Babayiğit
Eskisehir Osmangazi Univ, Fac Med, Dept Cardiol, Eskisehir, Turkiye
1 shared publication- Fatih Aydin
Department of Cardiology, Eskisehir City Hospital, Turkey
1 shared publication
Latest Publications
- Open Access
- 13 March 2026
- Published by Wiley in Annals of Noninvasive Electrocardiology
- Vol. 31 (2) , e70175
Fibrillatory Wave Amplitude: A Marker of Atrial Remodeling Rather Than a Chronological Clock?
- 13 March 2026
- Published by Wiley in Annals of Noninvasive Electrocardiology
- Vol. 31 (2) , e70175
Open AccessFibrillatory Wave Amplitude: A Marker of Atrial Remodeling Rather Than a Chronological Clock?
- 31 October 2025
- Published by SAGE Publications in Angiology
Impact of the Pre-Procedural Pan-Immune Inflammation Value on Long-Term Mortality in Patients With Peripheral Artery Disease Following Endovascular Treatment: A Comparative Study
Chronic inflammation significantly impacts the progression and prognosis of peripheral artery disease (PAD). The pan-immune inflammation value (PIV), an integrated biomarker reflecting various immune-inflammatory components, may provide superior prognostic insights for PAD patients treated by endovascular intervention. This retrospective analysis included 282 patients who underwent endovascular treatment for PAD between 2018 and 2022. Pre-procedural blood samples were used to calculate PIV and other inflammatory indices. The primary endpoint was long-term mortality, evaluated by receiver operating characteristic analyses and Cox proportional hazards modeling. PIV showed the highest predictive accuracy for mortality (area under curve [AUC] = 0.72), surpassing the neutrophil-to-lymphocyte ratio (NLR; AUC = 0.65), systemic immune-inflammation index (SII; AUC = 0.67), platelet-to-lymphocyte ratio (PLR; AUC = 0.61), and systemic inflammation response index (SIRI; AUC = 0.58). In multivariate analysis adjusted for significant confounders, pre-procedural PIV emerged as an independent predictor of mortality (HR [Hazard ratio]: 1.89; 95% CI: 1.42-2.51; P <.001). These findings highlight the superior clinical utility of PIV as a prognostic biomarker, demonstrating its enhanced effectiveness in risk stratification compared with other inflammatory indices such as NLR, SII, PLR, and SIRI in patients with PAD following endovascular intervention. The integration of PIV into routine clinical assessment may improve prognostic accuracy and facilitate more informed and individualized decision-making.
- 31 October 2025
- Published by SAGE Publications in Angiology
Impact of the Pre-Procedural Pan-Immune Inflammation Value on Long-Term Mortality in Patients With Peripheral Artery Disease Following Endovascular Treatment: A Comparative Study
Chronic inflammation significantly impacts the progression and prognosis of peripheral artery disease (PAD). The pan-immune inflammation value (PIV), an integrated biomarker reflecting various immune-inflammatory components, may provide superior prognostic insights for PAD patients treated by endovascular intervention. This retrospective analysis included 282 patients who underwent endovascular treatment for PAD between 2018 and 2022. Pre-procedural blood samples were used to calculate PIV and other inflammatory indices. The primary endpoint was long-term mortality, evaluated by receiver operating characteristic analyses and Cox proportional hazards modeling. PIV showed the highest predictive accuracy for mortality (area under curve [AUC] = 0.72), surpassing the neutrophil-to-lymphocyte ratio (NLR; AUC = 0.65), systemic immune-inflammation index (SII; AUC = 0.67), platelet-to-lymphocyte ratio (PLR; AUC = 0.61), and systemic inflammation response index (SIRI; AUC = 0.58). In multivariate analysis adjusted for significant confounders, pre-procedural PIV emerged as an independent predictor of mortality (HR [Hazard ratio]: 1.89; 95% CI: 1.42-2.51; P <.001). These findings highlight the superior clinical utility of PIV as a prognostic biomarker, demonstrating its enhanced effectiveness in risk stratification compared with other inflammatory indices such as NLR, SII, PLR, and SIRI in patients with PAD following endovascular intervention. The integration of PIV into routine clinical assessment may improve prognostic accuracy and facilitate more informed and individualized decision-making.
- 24 April 2023
- Published by Elsevier in Journal of Electrocardiology
- Vol. 81, 285
Electrocardiographic parameters associated with pacemaker induced cardiomyopathy
- 24 April 2023
- Published by Elsevier in Journal of Electrocardiology
- Vol. 81, 285
Electrocardiographic parameters associated with pacemaker induced cardiomyopathy